Table 4 Comparison of responders and non-responders to 5-ASA therapy

Age, mean ± SD (years)

42.8 ± 16.8

49.0 ± 17.6

0.16

Sex, M/F

24 (54.5%)/20 (45.5%)

12 (48.0%)/13 (52.0%)

0.625

BMI, mean ± SD (kg/m²)

21.7 ± 2.5

22.2 ± 3.1

0.49

History of smoking

17 (38.6%)

5 (20.0%)

0.18

Current alcohol consumption

13 (29.5%)

8 (32.0%)

1

Age at onset, mean ± SD (years)

35.1 ± 14.8

42.8 ± 17.2

0.064

Disease duration, median (range), years

3.0 (1–12)

3.0 (1–8)

0.55

Type

1

Extensive

24 (54.5%)

15 (60.0%)

Left-sided

15 (34.1%)

8 (32.0%)

Proctitis

5 (11.4%)

2 (8.0%)

Frequency of defecation per day, median (range)

4 (1–6)

5 (4–8)

0.046

Bloody stool

20 (45.5%)

19 (76.0%)

0.022

CRP, median (range), mg/dL

0.08 (0.04–0.33)

0.57 (0.09–2.8)

0.011

Alb, median (range), g/dL

4.3 (4.1–4.5)

3.9 (3.2–4.1)

 < 0.001

Plt, median (range), × 10⁴/μL

29.5 (22.5–33.4)

31.4 (26.9–36.8)

0.19

Fecal hemoglobin, median (range), ng/mL

710 (122–3938)

5608 (676–14,270)

0.012

CMV infection

0 (0%)

1 (25.0%)

0.36

MES, median (range)

2 (1–3)

3 (2–3)

0.005

Matts grade, median (range)

3 (2–4)

4 (4–5)

 < 0.001

Partial Mayo score

4 (3–6)

5 (4–6)

0.55

PR3-ANCA positive

21 (47.7%)

13 (52.0%)

0.81

PR3-ANCA, median (range), U/mL

2.5 (1.4–14.8)

3.9 (1.7–14.2)

0.20